Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (89)

III-01Clémence Rigaux

An approach for reducing the sample sizes of pediatric trials in Type 2 Diabetes Mellitus: longitudinal analysis versus standard analyses

Thursday 09:55-11:20

III-02Matthew Riggs

M-EASE-1: A Modelling and simulation study conducted to further characterize the efficacy of low-dose Empagliflozin as Adjunctive to inSulin thErapy (M-EASE) in Type 1 Diabetes Mellitus

Thursday 09:55-11:20

III-03François Riglet

Bayesian individual dynamic predictions of biomarkers and risk of event in joint modelling (with uncertainty): a comparison between Stan, Monolix and NONMEM

Thursday 09:55-11:20

III-04Christer Rimmler

Evaluating the Influence of Cardiopulmonary Bypass on the Pharmacokinetics of Cefuroxime using PBPK and PopPK Models

Thursday 09:55-11:20

III-05Viktor Rognås

Bounded Integer approach to model time-varying SOFA scores from patients with carbapenem resistant infections

Thursday 09:55-11:20

III-06Federico Romano

Predictive performance of a parasite growth dynamics model for the evaluation of anti-malarial drugs: a case study with mefloquine

Thursday 09:55-11:20

III-07Daniel Röshammar

Assessment of expected drug exposure relative maximum safety limits in early phase studies

Thursday 09:55-11:20

III-08Ryosuke Shimizu

Quantitative systems pharmacology modeling of thrombopoiesis and platelet life-cycle, and application for thrombocytopenia

Thursday 09:55-11:20

III-10Tomohisa Saito

The evaluation of a population pharmacokinetic model of Tofogliflozin with the data from healthy volunteers and T2DM patients

Thursday 09:55-11:20

III-11Louis Sandra

A population pharmacokinetic model for propofol in (pre)term neonates and infants independently accounting for size, gestational age (GA) and postnatal age (PNA).

Thursday 09:55-11:20

III-12Marina Savelieva

Modeling decline in cognition to decline in function in Alzheimer’s disease

Thursday 09:55-11:20

III-13Annika Schneider

A PBPK approach for simulating the effect of liver cirrhosis on drug PK

Thursday 09:55-11:20

III-14Rik Schoemaker

Performance of the SAEM and FOCEI algorithms in the open-source non-linear mixed effect modelling tool nlmixr

Thursday 09:55-11:20

III-15Jérémy Seurat

Comparison of Phase I combination therapy designs by clinical trial simulations to evaluate early tumor shrinkage

Thursday 09:55-11:20

III-16Dmitry Shchelokov

Physiologically based pharmacokinetic modeling of anti-PD-1 therapeutic antibodies

Thursday 09:55-11:20

III-17Soyoung Shin

Novel population approach to establish in vitro-in vivo correlation for drugs with site-dependent absorption

Thursday 09:55-11:20

III-18Christian Siebel

Development of an adaptive dosing approach for doxorubicin in paediatric cancer patients

Thursday 09:55-11:20

III-19Iryna Sihinevich

Mathematical Modeling of Glucose Homeostasis in Morbidly Obese Diabetic Patients Undergoing Roux-en-Y Gastric Bypass Surgery: An IMI DIRECT Study

Thursday 09:55-11:20

III-20Florian Simon

A generic PBPK model for predicting the impact of inflammation on midazolam pharmacokinetics

Thursday 09:55-11:20

III-21Noppaket Singkham

Pharmacogenetics-Based Population Pharmacokinetic Analysis for Dosing Optimization of Ritonavir-Boosted Atazanavir in Thai adult HIV-Infected Patients

Thursday 09:55-11:20

III-22Jaydeep Sinha

Extension of the Janmahasatian fat-free mass model to account for ethnicity-related bias

Thursday 09:55-11:20

III-23Erik Sjögren

A PBPK Framework to Predict Drug Exposure in Malnourished Children

Thursday 09:55-11:20

III-24Eunjung Song

Selection of optimal study design based on the bioequivalence simulation study in highly variable drugs

Thursday 09:55-11:20

III-25Elena Soto

Population Pharmacokinetic (PopPK) Modelling and Simulation of Pregabalin to Support Dose Recommendation in Paediatric Patients 1 month to <4 years of Age with Partial Onset Seizures (POS)

Thursday 09:55-11:20

III-26Tomas Sou

Translational PK and PKPD modelling for the analysis of preclinical in-vitro and in-vivo studies to predict efficacious human dose of apramycin

Thursday 09:55-11:20

III-27Viktoria Stachanow

Does dried blood spot data enrich our understanding of hydrocortisone pharmacokinetics in paediatric patients with adrenal insufficiency?

Thursday 09:55-11:20

III-28Felix Stader

Physiologically based pharmacokinetic modelling to identify pharmacokinetic parameters driving age-related changes in drug exposure in the elderly

Thursday 09:55-11:20

III-29Gabriel Stillemans

Simultaneous population pharmacokinetic modeling of darunavir and cobicistat in a cohort of HIV patients

Thursday 09:55-11:20

III-30Mark Stroh

Translation and Mechanistic Corroboration of the Preliminary Clinical Pharmacokinetics and Pharmacodynamics of a Masked, Tumor‑Activated anti-PD-L1 Antibody with Systems Pharmacology

Thursday 09:55-11:20

III-31Herbert Struemper

Population Pharmacokinetics of Belimumab Administered Intravenously in Children with Systemic Lupus Erythematosus

Thursday 09:55-11:20

III-32Sabine Stuebler

Systems biology model of the mucosal immune system

Thursday 09:55-11:20

III-33Suein Choi

contribution of trough concentration data for the evaluation of multiple-dose pharmacokinetics

Thursday 09:55-11:20

III-34Jesper Sundell

Pharmacokinetic variability of isoniazid, and its two major metabolites in patients co-infected with tuberculosis and HIV

Thursday 09:55-11:20

III-35Budi Octasari Susanto

Translational Model-Informed Selection of Tuberculosis Drug Combination Regimens for Early Clinical Development

Thursday 09:55-11:20

III-36Hadi Taghvafard

Modeling (a)symmetry of concentration-effect curves

Thursday 09:55-11:20

III-37Hiroyuki Takita

The dynamics of pharmacological effects aimed at gut wall: A framework for a nested-target-within-enterocyte (NTWE) model that accounts for turnover of target and cell

Thursday 09:55-11:20

III-38Lénaïg Tanneau

Evaluating potential link between liver enzyme abnormalities and bedaquiline exposure in multi-drug resistant tuberculosis patients

Thursday 09:55-11:20

III-39Joel Tarning

Severe acute malnutrition results in lower exposure in children treated with artemether-lumefantrine for uncomplicated malaria

Thursday 09:55-11:20

III-40David Ternant

Revisiting target-mediated elimination of therapeutic antibodies: the irreversible binding approximation

Thursday 09:55-11:20

III-41Mita Thapar

Population pharmacokinetic analysis of MSB11022 following administration in healthy subjects and rheumatoid arthritis patients.

Thursday 09:55-11:20

III-42Anders Thorsted

Model-based translation from piglets to healthy volunteers: Prediction of TNF-α and IL-6 time-courses in human endotoxin challenge studies

Thursday 09:55-11:20

III-43Tjokosela Tikiso

A pooled analysis of abacavir pharmacokinetics in HIV-infected African children: the effect of age, malnutrition, and common concomitant co-medications.

Thursday 09:55-11:20

III-44Pauline Traynard

New library of double absorptions PK models for the MonolixSuite, application to veralipride pharmacokinetics

Thursday 09:55-11:20

III-45Carlos Traynor

Towards personalised medicine in Non-Small Cell Lung Cancer: design of a forecasting model of disease-progression to overall survival.

Thursday 09:55-11:20

III-46Iñaki F. Trocóniz

A modelling platform for onco-immunological drugs in early drug development

Thursday 09:55-11:20

III-47Denise Feick

Physiologically-based pharmacokinetic modeling of the CYP2C8 perpetrator trimethoprim

Thursday 09:55-11:20

III-48Sami Ullah

Population pharmacokinetics of cefepime in critically ill patients with and without impaired renal function

Thursday 09:55-11:20

III-49Parth Upadhyay

Exploring the Relationship Between Midazolam Concentrations And Level Of Sedation In Critically-Ill Mechanically Ventilated Children Using Markov Modelling

Thursday 09:55-11:20

III-50David Uster

Predictive performance of population pharmacokinetic models for Bayesian forecasting of coagulation factor VIII in hemophilia A

Thursday 09:55-11:20

III-51Pavan Vaddady

Application of Bayesian Methodology to Inform Imipenem/Relebactam Pediatric Study Design

Thursday 09:55-11:20

III-52Cristina Vaghi

Population modeling of tumor growth curves, the reduced Gompertz model and prediction of the age of a tumor

Thursday 09:55-11:20

III-53Stijn van Beek

Population Pharmacokinetics and Model-Informed Precision Dosing of Isoniazid in Tuberculosis Patients

Thursday 09:55-11:20

III-54Arthur Van De Vyver

in vitro PK/PD modeling of immunological synapse-based tumor cell killing and immune activation to predict in vitro efficacy of T-Cell Bispecifics.

Thursday 09:55-11:20

III-55Louvina van der Laan

Pharmacokinetics and drug-drug interactions of lamivudine and abacavir administered with antituberculosis drugs in HIV-infected children with multidrug-resistant tuberculosis

Thursday 09:55-11:20

III-56Jan-Stefan van der Walt

A Population Pharmacokinetic Analysis to Explore the Effect of Hepatic Impairment on Abemaciclib Pharmacokinetics

Thursday 09:55-11:20

III-57Tamara van Donge

Methadone dosing strategies in preterm neonates can be simplified

Thursday 09:55-11:20

III-58Rob van Wijk

Nanoscale pharmacokinetics and pharmacodynamics of isoniazid treatment of tuberculosis in zebrafish larvae

Thursday 09:55-11:20

III-59Filippo Venezia

Preclinical Pharmacokinetic/Pharmacodynamic modeling to evaluate combination efficacy and the modification effect of oncology compounds with anti-angiogenic drugs (Sunitinib, Axitinib)

Thursday 09:55-11:20

III-60Diego Vera-Yunca

Pharmacokinetic-Pharmacodynamic model for Acute Intermittent Porphyria in porphyric mice treated with a new recombinant PBGD protein

Thursday 09:55-11:20

III-61Luka Verrest

Exploring variability in paromomycin pharmacokinetics in East African visceral leishmaniasis patients

Thursday 09:55-11:20

III-62Ludwig Vincent

How to improve the accuracy of Drug-Drug Interaction risk prediction for Mechanism Based Inhibitors

Thursday 09:55-11:20

III-63Janet Wade

Population PK analysis with full and reduced covariate models for Sym004, an antibody mixture targeting EGFR

Thursday 09:55-11:20

III-64Ulrika Wählby Hamrén

Longitudinal FEV1 and exacerbation risk in COPD: Quantifying the association using joint modelling

Thursday 09:55-11:20

III-65Wenyi Wang

Physiological Response to Endotoxin Infusion in the Piglet: Modelling of changes in hemodynamic outcomes

Thursday 09:55-11:20

III-66Shijun Wang

Comparison of approaches for estimating covariate effects in full random effects models

Thursday 09:55-11:20

III-67Zhigang Wang

A Pharmacokinetic-Pharmacodynamic model built on in vitro data predict the antibacterial effect of polymyxin B against Klebsiella pneumoniae in vivo

Thursday 09:55-11:20

III-68Linda Wanika

Investigating the relationship between Lactate Dehydrogenase and the occurrence of Chronic Lower Respiratory Diseases

Thursday 09:55-11:20

III-69Shayne Watson

Development and Evaluation of a Human Physiologically Based Pharmacokinetic Model to Assess a Mitigation Strategy for Risks Associated with Novel Monoclonal Antibodies

Thursday 09:55-11:20

III-70Sebastian Weber

Qualifying drug dosing regimens in pediatrics using Gaussian Processes

Thursday 09:55-11:20

III-71Ferdinand Weinelt

A joint pharmacokinetic model of piperacillin/tazobactam including mechanistic renal clearance in critically ill patients

Thursday 09:55-11:20

III-72Gustaf Wellhagen

Modelling UACR as a clinical endpoint

Thursday 09:55-11:20

III-73Quirin Werthner

Network-based mathematical modelling of HPV transmission and cervical cancer in Germany.

Thursday 09:55-11:20

III-74Sebastian Wicha

TDMxR: an open-source package for model-based therapeutic drug monitoring in R

Thursday 09:55-11:20

III-75Mélanie Wilbaux

Projecting MIW815 (ADU-S100) human tumor PK after intra-tumoral injection using a translational modeling approach combining pre-clinical and clinical data

Thursday 09:55-11:20

III-76Justin Wilkins

Population Pharmacokinetics analysis of M5717, a novel antimalarial agent

Thursday 09:55-11:20

III-77Francis Williams Ojara

Time-to-event analysis framework to evaluate the impact of paclitaxel exposure on peripheral neuropathy in patients with advanced non-small cell lung cancer receiving first-line chemotherapy

Thursday 09:55-11:20

III-78Jan-Georg Wojtyniak

Physiologically-based Pharmaokinetic Modelling of Metoprolol Drug-Drug-Gene Interactions with Paroxetine and CYP2D6

Thursday 09:55-11:20

III-79Dan Wright

Kinetic-pharmacodynamic models in the setting of non-linear drug elimination

Thursday 09:55-11:20

III-80Xia Li

A Physiologically-Based Pharmacokinetic Model of Voriconazole

Thursday 09:55-11:20

III-81Rujia Xie

Pharmacokinetic-Pharmacodynamic Analysis of Anidulafungin in Pediatric and Adult Patients with Invasive Fungal Infections

Thursday 09:55-11:20

III-82Estelle Yau

A global sensitivity analysis of the Rodgers and Rowland equations predicting drug distribution in PBPK models

Thursday 09:55-11:20

III-83Anyue Yin

Population pharmacokinetics and pharmacogenetics analysis of mitotane in adrenocortical carcinoma patients towards individualized dosing

Thursday 09:55-11:20

III-84Jinqiu Yin

Pharmacokinetic-pharmacodynamic modeling of colistin against Pseudomonas aeruginosa-associated biofilm infections

Thursday 09:55-11:20

III-85Sirin Yonucu

Explaining inter-species differences to anti-PDL1 cancer immunotherapy using a translational quantitative systems pharmacology approach

Thursday 09:55-11:20

III-86Jurij Aguiar Zdovc

Population pharmacokinetic modeling of cisplatin in patients with small cell lung cancer using informative priors

Thursday 09:55-11:20

III-87Yang Zhang

Ways to improve the efficiency of pharmacometric model implemented in R using deSovle – an example with a PK model for ADC

Thursday 09:55-11:20

III-88Chenyan Zhao

Colistin to overcome resistance to ciprofloxacin – Quantifying combined effects of colistin and ciprofloxacin against four E. coli strains with different ciprofloxacin susceptibility in an in silico PKPD model

Thursday 09:55-11:20

III-89Xuan Zhou

Model-Based Estimation of Probability of Pharmacological Success for CNS Compounds

Thursday 09:55-11:20

III-90Tom Zwart

Population pharmacokinetics and limited sampling of iohexol as a renal function marker

Thursday 09:55-11:20